Clinical Trials
21 trialsNCT00003615 2023-06-15
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT00211185 2020-03-18
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 2 Completed
NCT00117845 2019-11-19
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01401530 2018-11-23
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 1 Completed
NCT00460109 2017-04-18
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00082940 2017-01-19
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT00513188 2016-12-15
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
University of Miami
Phase NA Withdrawn
NCT00337987 2015-02-27
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Yale University
Phase 2 Completed
NCT00026429 2013-12-18
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00006345 2013-05-30
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00138164 2013-05-30
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00801918 2013-05-15
Denileukine Diftitox for Relapsed ALCL
Columbia University
Phase 2 Withdrawn
NCT00051025 2012-07-13
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
Eisai Inc.
Phase 2 Completed
NCT00224354 2012-05-21
CLONTAK
Baylor College of Medicine
Phase 1 Withdrawn
NCT00211276 2012-03-14
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
Eisai Inc.
Phase 2 Completed
NCT00493129 2012-02-08
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00055146 2009-04-17
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
Eisai Inc.
Phase 2 Completed
NCT00050999 2008-03-05
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Eisai Inc.
Phase 4 Completed
NCT00051012 2008-03-05
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
Eisai Inc.
Phase 4 Completed
NCT00211198 2008-03-05
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Eisai Inc.
Phase 4 Completed